Home > Dermatology > EADV 2019 > Late-Breaking News > Topical ruxolitinib effective in vitiligo

Topical ruxolitinib effective in vitiligo

EADV 2019

Vitiligo pathogenesis is driven by signalling through Janus kinase (JAK) 1 and 2. In a clinical trial, topical ruxolitinib cream produced substantial facial and total body repigmentation up to 1 year [1].

Vitiligo is a chronic autoimmune disease of the skin that targets melanocytes, resulting in patches of skin depigmentation [2]. Expression of interferon (IFN)-γ is increased in the lesional skin of patients. Neutralisation of IFN-γ prevents CD8(+) T-cell accumulation and depigmentation, suggesting a therapeutic potential for this approach [3]. Thus, JAK1/JAK2 inhibitors appear effective in vitiligo, presumably via inhibition of IFN-γ signalling in the skin [4].

Ruxolitinib cream across a dose range of 0.15 to 1.5% provided significant repigmentation of facial vitiligo lesion after 24 weeks of double-blind, vehicle-controlled treatment [5]. After the blinded study phase, all patients were re-randomised and then treated with 1.5% ruxolitinib cream fo...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on